imatinib mesylate has been researched along with Leiomyoblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Büchner-Steudel, P; Fleig, WE | 1 |
| Gebauer, B; Hohenberger, P; Reichardt, P; Wardelmann, E | 1 |
2 review(s) available for imatinib mesylate and Leiomyoblastoma
| Article | Year |
|---|---|
[Diagnosis and conservative treatment of gastrointestinal stromal tumors (GIST)].
Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; Endoscopy, Gastrointestinal; Endosonography; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyoma, Epithelioid; Leiomyosarcoma; Male; Mesenchymoma; Neurilemmoma; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Sex Factors; Tomography, X-Ray Computed | 2004 |
[Gastrointestinal stromal tumors (GIST)--current concepts of surgical management].
Topics: Benzamides; Chemotherapy, Adjuvant; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyoma; Leiomyoma, Epithelioid; Leiomyosarcoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neurilemmoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors | 2004 |